Joerg Moeller, M.D.
About Joerg Moeller, M.D.
Joerg Moeller, M.D., is the CEO and Executive Director of BenevolentAI and a Non-Executive Director at Secura Bio, Inc., with over 30 years of experience in the pharmaceutical industry.
Current Role as CEO and Executive Director at BenevolentAI
Joerg Moeller currently serves as the CEO and Executive Director at BenevolentAI, based in London, England. Since joining the company in early 2024, Moeller has succeeded François Nader and made substantial operational changes. One of the significant achievements under his leadership includes a collaboration with Merck KGaA that has the potential to generate up to $594 million in revenue. Additionally, the company announced positive top-line Phase Ia data for BEN-8744, a lead asset for treating ulcerative colitis. Moeller has also focused on strengthening the Executive Leadership Team at BenevolentAI.
Board Member at Secura Bio, Inc.
Joerg Moeller serves as a Non-Executive Director on the Board of Directors at Secura Bio, Inc., a role he performs remotely from the United States. His expertise in the pharmaceutical industry, particularly in the commercialization of oncology therapies, bolsters Secura Bio's strategic initiatives. Moeller's extensive experience and leadership skills contribute to guiding the company's mission and operations.
Previous Roles at LEO Pharma and BlueRock Therapeutics
Before joining BenevolentAI, Joerg Moeller was the Corporate EVP, Head of Global Research and Development at LEO Pharma from 2021 to 2023 in Copenhagen, Denmark. Additionally, he served on the Board of Directors at BlueRock Therapeutics from 2019 to 2020. In these roles, he contributed to advancing innovative therapeutic solutions and guided organizational strategy and operations. His tenure at LEO Pharma and BlueRock Therapeutics underscores his expertise in R&D and strategic leadership in the biopharmaceutical industry.
Extensive Career at Bayer AG
Joerg Moeller's career at Bayer AG spanned over 15 years, encompassing various senior leadership roles. From 2018 to 2020, he was the Corporate EVP, Head of Global R&D, and a member of the Pharmaceuticals Executive Committee. Prior to this, from 2014 to 2017, he held the position of Corporate EVP, Head of Global Development. His earlier roles include Corporate Senior Vice President, Head of Global Clinical Development, and Vice President, Head of Strategic Drug Development Cardiovascular. Moeller's leadership at Bayer AG was instrumental in the development and approval of numerous first-in-class medicines across multiple therapeutic areas.
Education and Medical Background
Joerg Moeller holds a medical degree (M.D.) from Ruhr University Bochum, where he studied from 1984 to 1990. Complementing his medical education, Moeller pursued further business management training at the Center for Creative Leadership and completed the Advanced Management Program at IESE Business School. His extensive educational background in both medicine and business management has equipped him to drive innovation and leadership in the pharmaceutical industry.